These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 23399039

  • 1. MRI assessment of relapsed glioblastoma during treatment with bevacizumab: volumetric measurement of enhanced and FLAIR lesions for evaluation of response and progression--a pilot study.
    Pichler J, Pachinger C, Pelz M, Kleiser R.
    Eur J Radiol; 2013 May; 82(5):e240-5. PubMed ID: 23399039
    [Abstract] [Full Text] [Related]

  • 2. Automatic multi-modal MR tissue classification for the assessment of response to bevacizumab in patients with glioblastoma.
    Liberman G, Louzoun Y, Aizenstein O, Blumenthal DT, Bokstein F, Palmon M, Corn BW, Ben Bashat D.
    Eur J Radiol; 2013 Feb; 82(2):e87-94. PubMed ID: 23017192
    [Abstract] [Full Text] [Related]

  • 3. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
    Huang RY, Rahman R, Hamdan A, Kane C, Chen C, Norden AD, Reardon DA, Mukundun S, Wen PY.
    Cancer; 2013 Oct 01; 119(19):3479-88. PubMed ID: 23821555
    [Abstract] [Full Text] [Related]

  • 4. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.
    Artzi M, Bokstein F, Blumenthal DT, Aizenstein O, Liberman G, Corn BW, Ben Bashat D.
    Eur J Radiol; 2014 Jul 01; 83(7):1250-1256. PubMed ID: 24809637
    [Abstract] [Full Text] [Related]

  • 5. GPU-accelerated nonparametric kinetic analysis of DCE-MRI data from glioblastoma patients treated with bevacizumab.
    Hsu YH, Ferl GZ, Ng CM.
    Magn Reson Imaging; 2013 May 01; 31(4):618-23. PubMed ID: 23200680
    [Abstract] [Full Text] [Related]

  • 6. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.
    Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel PS, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J.
    Radiology; 2009 Jul 01; 252(1):182-9. PubMed ID: 19561256
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
    Schaub C, Greschus S, Seifert M, Waha A, Blasius E, Rasch K, Landwehr C, Mack F, Schäfer N, Stuplich M, Kebir S, Vilz B, Scheffler B, Boström J, Simon M, Urbach H, Glas M, Herrlinger U.
    Oncology; 2013 Jul 01; 85(3):191-5. PubMed ID: 24008924
    [Abstract] [Full Text] [Related]

  • 10. MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma.
    Kickingereder P, Radbruch A, Burth S, Wick A, Heiland S, Schlemmer HP, Wick W, Bendszus M, Bonekamp D.
    Radiology; 2016 May 01; 279(2):542-52. PubMed ID: 26579564
    [Abstract] [Full Text] [Related]

  • 11. Lymphomas and glioblastomas: differences in the apparent diffusion coefficient evaluated with high b-value diffusion-weighted magnetic resonance imaging at 3T.
    Doskaliyev A, Yamasaki F, Ohtaki M, Kajiwara Y, Takeshima Y, Watanabe Y, Takayasu T, Amatya VJ, Akiyama Y, Sugiyama K, Kurisu K.
    Eur J Radiol; 2012 Feb 01; 81(2):339-44. PubMed ID: 21129872
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study.
    Sawlani RN, Raizer J, Horowitz SW, Shin W, Grimm SA, Chandler JP, Levy R, Getch C, Carroll TJ.
    Radiology; 2010 May 01; 255(2):622-8. PubMed ID: 20413772
    [Abstract] [Full Text] [Related]

  • 17. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
    Kickingereder P, Brugnara G, Hansen MB, Nowosielski M, Pflüger I, Schell M, Isensee F, Foltyn M, Neuberger U, Kessler T, Sahm F, Wick A, Heiland S, Weller M, Platten M, von Deimling A, Maier-Hein KH, Østergaard L, van den Bent MJ, Gorlia T, Wick W, Bendszus M.
    Radiology; 2020 Oct 01; 297(1):164-175. PubMed ID: 32720870
    [Abstract] [Full Text] [Related]

  • 18. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.
    Ellingson BM, Kim HJ, Woodworth DC, Pope WB, Cloughesy JN, Harris RJ, Lai A, Nghiemphu PL, Cloughesy TF.
    Radiology; 2014 Apr 01; 271(1):200-10. PubMed ID: 24475840
    [Abstract] [Full Text] [Related]

  • 19. Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma.
    Nowosielski M, Wiestler B, Goebel G, Hutterer M, Schlemmer HP, Stockhammer G, Wick W, Bendszus M, Radbruch A.
    Neurology; 2014 May 13; 82(19):1684-92. PubMed ID: 24727314
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.